Article

New Issue Alert: CURE Spring

We've got a sneak peek at what’s inside CURE®'s spring issue.

Does cannabis have a positive effect on patients with cancer? Although researchers are still conducting studies to gain further evidence, its popularity is driving its legalization for therapeutic use. Our cover story, Flower Power, covers all the angles.

Next, patients with head and neck cancer are Keeping the Options Open. Learn about the less toxic treatment choices that are moving to be used as initial therapy for patients ­— and, hopefully, improving their quality of life.

And, at the age of 21, one woman was told she had the BRCA1 gene mutation, which meant she had a 55 to 85 percent lifetime risk of developing breast cancer. Years later, and after undergoing a double, prophylactic mastectomy, she learned she was misdiagnosed. Her story, plus how she’s Making Lemonade from life’s lemons.

To read these stories and more, visit curetoday.com/publications and click on the latest CURE® cover. Or, ensure you don’t miss a story when you subscribe to new issue alerts. Visit curetoday.com/email-profile for more information.

And, as always, thanks for reading.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Image of doctor with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.